- Deutsche Bank analyst George Hill downgraded 1Life Healthcare ( ONEM ) to Hold from Buy with a price target of $12, up from $11.
- The analyst, however, has a "hard time justifying" a share price above the $12-$13 range, implying 10% upside to the current share price.
- He sees challenges to 1Life's core business growth resulting from the slowing economy.
- Additionally, he's meaningfully below consensus on out-year earnings estimates, meaning he expects negative revisions.
- Further, Hill suspects that if a buyout were to occur, much of the premium has already been priced into the stock.
- 1Life Healthcare's SA Quant Rating stands with a Hold whereas, Wall St. Analysts Rating says Buy (8 Very Bullish, 5 Bullish).
- Since the start of 2022, 1Life Healthcare's shares were down around 46% , and over a period of one year, shares were down around 68% .
- Shares are currently -6.41% to $9.78 today.
For further details see:
1Life Healthcare downgraded to Hold from Buy at Deutsche Bank